BioCentury
ARTICLE | Clinical News

AGI-1067: Phase III data

August 4, 2008 7:00 AM UTC

Top line data from the double-blind, international Phase III ANDES trial in 887 patients who completed 6 months of treatment showed that 75 and 150 mg daily doses of oral AGI-1067 met the primary endp...